Earnings summaries and quarterly performance for Korro Bio.
Executive leadership at Korro Bio.
Board of directors at Korro Bio.
Research analysts covering Korro Bio.
Recent press releases and 8-K filings for KRRO.
Korro Bio, Inc. Hosts Analyst Day, Highlights KRRO-121 Program
KRRO
New Projects/Investments
- Korro Bio, Inc. hosted a virtual Analyst Day on January 27, 2026, to discuss its drug candidate KRRO-121.
- KRRO-121 is positioned as a potential first-in-class treatment for ammonia control, addressing conditions such as Urea Cycle Disorders (UCD) and Hepatic Encephalopathy (HE).
- Preclinical data for KRRO-121 showed robust ammonia control in mouse models and no adverse safety signals in non-human primates.
- A regulatory submission for KRRO-121 to enable a First-in-Human (FIH) trial is anticipated in the second half of 2026.
- The company projects KRRO-121 to have blockbuster potential, with an estimated market opportunity of $1.5 billion in the U.S. for UCD and over $2 billion in the U.S. for HE.
Jan 27, 2026, 2:15 PM
Korro Bio Details KRRO-121 Program and Market Opportunity
KRRO
Product Launch
New Projects/Investments
- Korro Bio is advancing KRRO-121, an RNA editing therapeutic designed to stabilize glutamine synthetase (GS) in the liver, aiming to control high ammonia levels in patients with Urea Cycle Disorders (UCDs) and Hepatic Encephalopathy (HE).
- Preclinical data for KRRO-121 demonstrated robust ammonia control in UCD mouse models and a clean toxicology profile, supporting its pan-UCD applicability and potential for diet liberalization.
- The company anticipates submitting for regulatory approval for its first human trial of KRRO-121 in the second half of 2026.
- Korro Bio estimates the market opportunity for KRRO-121 to be $1.5 billion for UCD (approximately 9,000 addressable patients in the US and Europe) and over $2 billion for HE (over 200,000 addressable patients in the US and Europe).
- KRRO-121 is positioned to offer a differentiated approach with potential for convenient weekly or monthly subcutaneous administration, further crisis reduction, and diet liberalization, addressing current unmet needs.
Jan 27, 2026, 1:00 PM
Korro Bio Updates Corporate Presentation with Key Pipeline and Collaboration Changes
KRRO
New Projects/Investments
- Korro Bio, Inc. updated its corporate presentation on January 15, 2026, for use in meetings with investors, analysts, and others.
- The company announced a 12-month pause in its Novo Nordisk collaboration, which began in November 2025.
- Korro Bio is terminating the REWRITE clinical trial for its KRRO-110 program in Alpha-1 Antitrypsin Deficiency (AATD).
- Key anticipated milestones include nominating a development candidate for its AATD program in the first half of 2026 and a regulatory filing for KRRO-121 in the second half of 2026.
Jan 15, 2026, 9:05 PM
Korro Bio Provides Pipeline Updates and Cash Runway Outlook
KRRO
New Projects/Investments
Guidance Update
- Korro Bio, Inc. anticipates its cash runway to extend into H2 2027.
- The company plans a regulatory filing for KRRO-121 in Hyperammonemia in H2 2026, with a workshop scheduled for January 27, 2026. KRRO-121 is estimated to have blockbuster potential, addressing market opportunities of $1.5 billion for Urea Cycle Disorders and over $2 billion for Hepatic Encephalopathy.
- Korro Bio is terminating the REWRITE clinical trial for KRRO-110 in Alpha-1 Anti-Trypsin Deficiency (AATD) but is developing a new GalNAc-conjugated AATD construct, with a development candidate anticipated in 1H 2026.
- For the next-generation AATD program, the company has demonstrated over 90% editing of the SERPINA1 transcript using GalNAc delivery in vivo.
Jan 15, 2026, 6:30 PM
Korro Bio Updates on Pipeline Progress and 2026 Milestones
KRRO
New Projects/Investments
Guidance Update
- Korro Bio's lead program, Korro 121, targeting elevated ammonia in multiple indications, is anticipated to have a regulatory filing in the second half of 2026 and enter the clinic shortly thereafter.
- The company terminated its Korro 110 program due to preclinical data not meeting expectations and structural integrity issues, but has developed a next-generation Alpha-1 product with significantly improved potency, aiming for development candidate nomination in the first half of 2026.
- Korro Bio is also advancing pipeline programs for AMPK gamma-1 (targeting metabolic stabilization for MASH) and an ALS program (restoring function).
- The company projects a cash runway into the second half of 2027.
Jan 15, 2026, 6:30 PM
Korro Bio Provides Updates on Pipeline and Cash Runway
KRRO
Product Launch
New Projects/Investments
Guidance Update
- Korro Bio announced the termination of its Korro 110 program for Alpha-1 antitrypsin deficiency due to data not meeting expectations and issues with the product's structural integrity in patients.
- The company's lead program, Korro 121, a Gal-conjugated liver-focused therapy aimed at reducing ammonia, is anticipated to have a regulatory filing in the second half of 2026 and enter the clinic shortly thereafter.
- Significant progress has been made on a next-generation Alpha-1 product, demonstrating greater than 90% editing in an in vivo model and achieving potency almost three logs more than Korro 110, with a development candidate expected in the first half of 2026.
- Korro Bio is also advancing new programs, including an AMPK gamma-1 modulator for liver health and MASH, and an ALS program focused on restoring function by addressing TDP-43 pathology.
- The company expects its cash runway to extend into the second half of 2027.
Jan 15, 2026, 6:30 PM
Korro Bio Provides Update on RNA Editing Pipeline and 2026 Milestones
KRRO
New Projects/Investments
Guidance Update
- Korro Bio's lead program, Korro 121, a Gal-conjugated liver-focused program aimed at reducing ammonia, is anticipated to have a regulatory filing in the second half of 2026 and enter the clinic shortly thereafter. An analyst day for Korro 121 is scheduled for January 27.
- The company terminated its previous lead program, Korro 110, due to data not meeting expectations and issues with the product's structural integrity in patients.
- Korro Bio has made significant progress on a next-generation Alpha-1 product, achieving over 90% editing in vivo with three logs more potency than Korro 110, and expects to nominate a development candidate in the first half of 2026.
- The company is also advancing programs for AMPK gamma-1 (targeting liver health and MASH) and ALS (restoring TDP-43 function).
- Korro Bio has a cash runway into the second half of 2027.
Jan 15, 2026, 6:30 PM
Korro Bio Reports Q3 2025 Financial Results and Strategic Restructuring
KRRO
Earnings
Layoffs
Guidance Update
- Korro Bio reported $102.5 million in cash, cash equivalents, and marketable securities as of September 30, 2025, and expects this to fund operating expenses and capital expenditure requirements into the second half of 2027.
- The company is implementing a strategic restructuring, including an approximately 34% reduction in its workforce, to extend its cash runway and focus resources on high-potential GalNAc-conjugated programs.
- For its KRRO-110 program in Alpha-1 Antitrypsin Deficiency (AATD), functional protein was produced but did not reach projected levels, leading to a pivot to GalNAc delivery with a development candidate nomination expected in the first half of 2026.
- Korro Bio nominated KRRO-121 as its next development candidate for hyperammonemia, with a regulatory filing to enable a first-in-human trial anticipated in the second half of 2026.
- Collaboration revenue for the three months ended September 30, 2025, was $1.1 million, compared to no collaboration revenue for the three months ended September 30, 2024.
Nov 12, 2025, 9:08 PM
Korro Bio Updates on KRRO-110 Clinical Progress and Financial Runway
KRRO
New Projects/Investments
Guidance Update
- Korro Bio's lead program, KRRO-110 for Alpha-1 antitrypsin deficiency, has dosed patients in its REWRITE clinical study, with two cohorts enrolled and dose escalation progressing as of March 4, 2025.
- The company expects to release interim data from the single-ascending dose (SAD) study, focusing on safety, tolerability, and activity, in the second half of 2025.
- Korro Bio plans to nominate its second clinical candidate (targeting the liver with sub-Q delivery) later in 2025 and reported a cash runway extending into the second half of 2026.
- The estimated peak sales for the Alpha-1 antitrypsin deficiency market in the U.S. are approximately $3 billion.
Mar 4, 2025, 4:50 PM
Fintool News
In-depth analysis and coverage of Korro Bio.
Corporate
Korro Bio Unveils $3.5B RNA Editing Play at Analyst Day, Eyes 2026 Clinical Entry
Jan 27
Corporate
Korro Bio Unveils KRRO-121 Preclinical Data at Analyst Day, Targets $3.5B Ammonia Control Market
Jan 27
Corporate
Korro Bio Unveils KRRO-121 at Analyst Day: RNA Editing Pivot Targets $3.5B Ammonia Control Market
Jan 27
Corporate
Korro Bio Unveils KRRO-121 at Analyst Day, Eyes $3.5 Billion Ammonia Market with First-in-Class RNA Editing Approach
Jan 27
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more